![Johan Dighed](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Johan Dighed
Director/Board Member at PROMIMIC AB
Johan Dighed active positions
Companies | Position | Start | End |
---|---|---|---|
KAROLINSKA DEVELOPMENT AB | General Counsel | 2020-04-30 | - |
PROMIMIC AB | Director/Board Member | 2020-12-31 | - |
AnaCardio AB
![]() AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Director/Board Member | - | - |
KDev Oncology AB
![]() KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Director/Board Member | - | - |
KDev Investments AB
![]() KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Director/Board Member | - | - |
KCIF Fund Management AB | Director/Board Member | - | - |
KD Incentive AB | Director/Board Member | - | - |
Modus Therapeutics AB
![]() Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Director/Board Member | - | - |
Career history of Johan Dighed
Former positions of Johan Dighed
Companies | Position | Start | End |
---|---|---|---|
DSK Hyp AG
![]() DSK Hyp AG Major BanksFinance DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany. | General Counsel | - | - |
Training of Johan Dighed
University of Lund | Graduate Degree |
Statistics
International
Sweden | 10 |
Germany | 2 |
Operational
Director/Board Member | 7 |
General Counsel | 2 |
Graduate Degree | 1 |
Sectoral
Health Technology | 5 |
Finance | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
KAROLINSKA DEVELOPMENT AB | Finance |
PROMIMIC AB | Health Technology |
Private companies | 7 |
---|---|
DSK Hyp AG
![]() DSK Hyp AG Major BanksFinance DSK Hyp AG provides banking and financial services to corporate customers, institutions and private individuals. The bank operates through corporate and institutions division which comprises of merchant banking and securities. The company is headquartered in Frankfurt am Main, Germany. | Finance |
AnaCardio AB
![]() AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |
KDev Oncology AB
![]() KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Commercial Services |
KDev Investments AB
![]() KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden. | Health Technology |
KCIF Fund Management AB | |
KD Incentive AB | |
Modus Therapeutics AB
![]() Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
- Stock Market
- Insiders
- Johan Dighed
- Experience